Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Based on advanced technological platforms and an integrated team of wet lab scientists, translational researchers, medicinal chemists, and bioinformaticians, AccelBio provides customized support to drive biomedical projects towards successful translation. Our expertise enables risk mitigation and acceleration across the drug discovery pipeline, including critical stages such as target validation, hit identification, lead optimization, and preclinical development.
Target Validation
Target Validation
We give support to testing disease relevance of biological targets and predicting potential therapeutic and off-side effects of its modulation, using combined in vitro, in silico and in vivo approaches. Used in silico methods also allow us to predict how target modulation influences drug efficacy and safety profiles, enabling more informed and streamlined decision-making in early-stage drug development.
Hit Discovery
Hit Discovery
We can support identification of molecules with activity against specific biological targets. This involves the development of tailored compound screening assays based on the target’s nature. Our primary strategy combines in silico techniques with high-throughput screening (HTS) to enhance the efficiency and precision of hit identification, accelerating the early stages of the drug discovery pipeline.
Lead Optimization
Lead Optimization
We offer organoid-based assay development and drug testing services. Accelbio holds in house advanced kidney, brain and heart organoids. We also develop new models and design or perform assays to evaluate efficacy, toxicity, and disease-specific responses, according to project needs. These physiologically relevant 3D&2D models closely mimic human tissue architecture and function, enabling more predictive and translational preclinical studies.
Pre-Clinical Studies
Pre-Clinical Studies
Early proof-of-concept efforts combine in silico predictions with wet lab experimental studies to assess lead compound efficacy, toxicity, and pharmacological properties. This includes comprehensive pharmacokinetic and pharmacodynamic evaluations to determine the therapeutic potential and safety profile of candidate molecules.
Organoids
Organoids
We offer organoid-based assay development and drug testing services. Accelbio holds in house advanced kidney, brain and heart organoids. We also develop new models and design or perform assays to evaluate efficacy, toxicity, and disease-specific responses, according to project needs. These physiologically relevant 3D&2D models closely mimic human tissue architecture and function, enabling more predictive and translational preclinical studies.
Consulting
Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy text ever since the 1500s, when an unknown printer took a galley of type and scrambled it to make a type specimen book.
Creating a translational roadmap from research to market helps reduce risk and improves your project's chances of success. Our consulting services include support to the design of Target Drug Profiles, Development and Business Plans or performing Market Analysis for your asset/project. We also support you in defining industry-based best practices, leading to high-quality drug candidates.
Target Drug Profile
Target Drug Profile
We support the design of target drug profiles for individual assets, addressing desired characteristics for a new drug or therapy to reach the market. It includes definition of intended use, target population and key performance features. This document serves as reference guide for researcher teams through the drug development process, providing clear criteria and goals that a successful candidate should ideally meet.
Market Analysis and Positioning
Market Analysis and Positioning
Our team has wide experience in industry and technology transfer. We support comprehensive assessment of market potential and competitive landscape across multiple therapeutic areas, identifying strategic opportunities for differentiation and value creation. This analysis enables informed decision-making and helps position assets effectively within the market.
Development Plan
Development Plan
We support the development of clear and objective drug development plans, outlining key milestones, timelines, and major decision points. These plans include well-defined go/no-go criteria to guide progression through each phase, ensuring a structured and efficient path from discovery to clinical development.
Regulatory Strategy and Compliance
Regulatory Strategy and Compliance
Our team has extensive industry-based R&D experience, including CRO environments and adherence to industry guidelines. We bring industry best practices into drug discovery projects conducted in various laboratory settings. We support ensuring strict compliance with regulatory standards and best practices through the discovery and development process, leading to high-quality candidates.
Business Plan
Business Plan
Our team can support the development of a comprehensive business plan that outlines the goals, strategic objectives, and operational pathways needed to effectively leverage a drug asset. This plan serves as a clear roadmap for achieving the project’s commercial objectives, guiding decision-making and aligning stakeholders throughout the development lifecycle.
